

FAAST

France Alzheimer Actualités Scientifiques & Thérapeutiques



3 juin 2024

Maison de la Chimie

28 Rue Saint-Dominique - Paris



**FRANCE
ALZHEIMER**
& MALADIES APPARENTÉES

8h30 – Café d'accueil

9h00 – Introduction de la journée

9h15 – Conférence Plénière de LAMBERT Jean-Charles (Institut Pasteur, Lille) **Genetics of Alzheimer's disease: where we are and where we are going**

LAMBERT Jean-Charles (Institut Pasteur, Lille)

10h00 – Symposium 1 – Physiopathologie

Modération

Flavie STRAPPAZZON et Marc DHENAIN

BUISSON Alain (Institut des neurosciences, Grenoble)

Transmissible long-term neuroprotective and pro-cognitive effects of 1-42 beta-amyloid with A2T icelandic mutation in an Alzheimer's disease mouse model

PLANEL Emmanuel (Université Laval, Québec)

Thermotherapy for tauopathies

CASTELOT Romain (Cancer and Brain Genomics, Rouen)

SORL1 missense variants identified in Alzheimer's disease patients result in higher production of intracellular A β -seeding competent species

STRAPPAZZON Flavie (Pathophysiologie et génétique du neurone et du muscle, Lyon)

A natural variant of the autophagic receptor NDP52 counteracts phospho-TAU accumulation and emerges as a protective factor for Alzheimer Disease

11h15 – Session Parrainage Jeunes Chercheurs 1

Modération

Kevin RABIAN

BORDIER Chiara (Institut de Neurophysiopathologie, Marseille)

Role of ApoE4 in the interrelation between microglia, neurons, and astrocytes leading to tau-mediated synaptic impairments and loss in AD

DUQUESNE Laurine (Optimisation thérapeutique en Neuropsychopharmacologie, Paris)

Identification of biomarkers of the GBA1 pathway in dementia with Lewy bodies

GARCIA Lolie (Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses)

Impact of deregulation of the microglial inflammatory profile on the evolution of Alzheimer's disease.

GLASTRA Alexandre (CRSA, Paris)

Tolerogenic vaccination as an immunotherapy targeting T cells in Alzheimer's disease and other tauopathies

LESTRA Thaïs (Institut de Neurophysiopathologie, Marseille)

Mechanisms of action of MT5-MMP in Alzheimer's disease and therapeutic modulation using viral-mediated transgenic strategies.

11h45 – Session poster

12h15 – Pause déjeuner + session poster

13h15 – Symposium 2 – Traitements pharmacologiques innovants

Modération

Sylvie CLAEYSEN et Nicolas SERGEANT

ROCHAIS Christophe (CERMN, Caen)

Design and evaluation of pleiotropic prodrugs able to modulate the serotonergic system in the context of Alzheimer's disease

DANIS Clément (Institut Pasteur, Lille)

In solution dimerization of a single domain antibody as an original mechanism for inhibiting tau neuronal internalization

PIETRI Mathéa (UMR-S 1124, Paris)

Environmental nanoparticles and Alzheimer's Disease onset: a critical role of PrPC signaling

14h05 – Session Parrainage Jeunes Chercheurs 2

Modération

Kevin RABIAN

ALEND A Ugo (Institut de Génomique Fonctionnelle, Montpellier)

Nanobodies targeting metabotropic glutamate receptors as potential therapeutic tools for Alzheimer's disease

CHAHLA Charbel (Institut de Neurophysiopathologie, Marseille)

Impact of the AT8 epitope phosphorylation on tau aggregation, propagation, and neurotoxicity.

DUPUIS Léo (Laboratoire des Maladies Neurodégénératives, Fontenay-aux-Roses)

Impact of tau and amyloid-beta lesions on the transcriptome expression in a primate model of Alzheimer's Disease.

EL HADDAD Inès (CRSA, Paris)

Preclinical evaluation of a Treg-targeting immunomodulatory treatment in a mouse model of Alzheimer-like tau pathology

GABRIEL Vincent (Laboratoire ICube, Strasbourg)

Gray matter volume correlates with CSF A β 42 biomarker in dementia with Lewy bodies: Insula, Claustrum, Striatum and Thalamus

PRIEUR Matthieu (Institut de Génomique Fonctionnelle, Montpellier)

Investigating the role of Clec7a in microglia function: Implications as an Early molecular target in Alzheimer's Disease

15h00 – Pause-café + session poster

15h30 – Symposium 3 – Biomarqueurs

Modération

Sylvain LEHMANN et Emmanuel COGNAT

Conférence Plénière

CSF and blood biomarkers in Alzheimer's disease and related disorders

LEHMANN Sylvain (Institut des Neurosciences, Montpellier)

OOSTERLYNCK Marie (Lille Neuroscience & Cognition, Lille)

Tau proteome analysis of Alzheimer's Disease brain extracellular vesicles reveals PHF6 peptide as core for pathological tau seeding

GIANGRANDE Chiara (Laboratoire National de Métrologie et d'Essais, Paris)

Standardisation of Measurements of Neurodegenerative Disease Biomarkers: The NEuroBioStand Project

16h40 – Symposium 4 – Neuroinflammation et neuroimmunologie

Modération

Hélène HIRBEC et Guillaume DOROTHEE

HIRBEC Hélène (Institut de Génomique Fonctionnelle, Montpellier)

Early microglia reaction in the APP/PS1 mouse model of Alzheimer's Disease: a key to understand the disease initiation

GRATUZE Maud (Institut de Neurophysiopathologie, Marseille)

TREM2 in Alzheimer's disease: Why is it so complicated?

MATTA Karen (CRSA, Paris)

Deciphering The Role of CD4 and CD8 T cells in the Pathophysiology of Alzheimer's Disease and Other Tauopathy

17h40 – Remise des prix

18h00 – Clôture du colloque

Inscription gratuite et obligatoire:
<https://faast.sciencesconf.org/>

Pour plus d'informations contacter

Kevin RABIAN

01 42 97 48 91

k.rabiant@francealzheimer.org

Aurora DOMINICI

01 70 22 21 25

a.dominici@francealzheimer.org

**Union national des associations
France Alzheimer et maladies apparentées**

11, rue Tronchet – 75008 Paris

www.francealzheimer.org

